These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 26093777)

  • 1. Adverse reactions to infliximab and the outcome of desensitization.
    Mourad AA; Boktor MN; Yilmaz-Demirdag Y; Bahna SL
    Ann Allergy Asthma Immunol; 2015 Aug; 115(2):143-6. PubMed ID: 26093777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: a prospective multicenter cohort study.
    Babouri A; Roblin X; Filippi J; Hébuterne X; Bigard MA; Peyrin-Biroulet L
    J Crohns Colitis; 2014 Feb; 8(2):161-5. PubMed ID: 23994253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
    Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ
    Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab infusion time in patients with inflammatory bowel diseases: is longer really safer?
    Belhassan M; Zeitoun JD; Lefevre JH; Charachon A; Amiot A; Le Baleur Y; Sobhani I; Delchier JC
    Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):189-92. PubMed ID: 23246140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability of one hour 10 mg/kg infliximab infusions in patients with inflammatory bowel disease.
    Babouri A; Buisson A; Bigard MA; Peyrin-Biroulet L
    J Crohns Colitis; 2013 Mar; 7(2):129-33. PubMed ID: 22472090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
    Jahnsen J; Detlie TE; Vatn S; Ricanek P
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid infliximab infusions in pediatric inflammatory bowel disease.
    Yeckes AR; Hoffenberg EJ
    J Pediatr Gastroenterol Nutr; 2009 Jul; 49(1):151-4. PubMed ID: 19516188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
    Vande Casteele N; Ferrante M; Van Assche G; Ballet V; Compernolle G; Van Steen K; Simoens S; Rutgeerts P; Gils A; Vermeire S
    Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab in inflammatory bowel disease: attention to adverse events.
    Uyanikoglu A; Ermis F; Akyuz F; Pinarbasi B; Baran B; Aydogan T; Demir K; Besisik F; Kaymakoglu S
    Eur Rev Med Pharmacol Sci; 2014 Aug; 18(16):2337-42. PubMed ID: 25219835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study.
    Breynaert C; Ferrante M; Fidder H; Van Steen K; Noman M; Ballet V; Vermeire S; Rutgeerts P; Van Assche G
    Am J Gastroenterol; 2011 Apr; 106(4):778-85. PubMed ID: 21407184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.
    Fréling E; Baumann C; Cuny JF; Bigard MA; Schmutz JL; Barbaud A; Peyrin-Biroulet L
    Am J Gastroenterol; 2015 Aug; 110(8):1186-96. PubMed ID: 26195181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital.
    Seiderer J; Göke B; Ochsenkühn T
    Digestion; 2004; 70(1):3-9. PubMed ID: 15297773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model.
    Crandall WV; Mackner LM
    Aliment Pharmacol Ther; 2003 Jan; 17(1):75-84. PubMed ID: 12492735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting.
    Checkley LA; Kristofek L; Kile S; Bolgar W
    Dig Dis Sci; 2019 Mar; 64(3):855-862. PubMed ID: 30311152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors influencing acute infusion reactions in inflammatory bowel disease patients treated with infliximab in the era of scheduled maintenance therapy.
    Duron C; Goutte M; Pereira B; Bommelaer G; Buisson A
    Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):705-11. PubMed ID: 25856689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment.
    Marits P; Landucci L; Sundin U; Davidsdottir L; Nilsson J; Befrits R; Wikström AC; Eberhardson M
    J Crohns Colitis; 2014 Aug; 8(8):881-9. PubMed ID: 24486178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of premedication with intravenous corticosteroids and antihistaminics in preventing infusion reactions to infliximab].
    Bermejo F; López San Román A; Algaba A; van Domselaar M; Carneros JA; Rivero M; Piqueras B; Valer MP
    Gastroenterol Hepatol; 2008 Dec; 31(10):629-32. PubMed ID: 19174078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre.
    Wee JS; Petrof G; Jackson K; Barker JN; Smith CH
    Br J Dermatol; 2012 Aug; 167(2):411-6. PubMed ID: 22404545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab.
    Thiebault H; Boyard-Lasselin P; Guignant C; Guillaume N; Wacrenier A; Sabbagh C; Rebibo L; Brazier F; Meynier J; Nguyen-Khac E; Dupas JL; Goëb V; Fumery M
    Eur J Gastroenterol Hepatol; 2016 Aug; 28(8):876-81. PubMed ID: 27101404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of infliximab in pediatric patients with inflammatory bowel disease.
    Serrano MS; Schmidt-Sommerfeld E; Kilbaugh TJ; Brown RF; Udall JN; Mannick EE
    Ann Pharmacother; 2001; 35(7-8):823-8. PubMed ID: 11485127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.